Comparing Adefovir and Lamivudine for Chronic Hepatitis B
Author Information
Author(s): Pradeep Kumar S Medhi, Subhash Asim Mohammad Das, Bhudev C Gondal, Ranjana Kar, Premashis Kar
Primary Institution: Maulana Azad Medical College, New Delhi, India
Hypothesis
The study aims to compare the efficacy of adefovir and lamivudine in treating chronic hepatitis B.
Conclusion
Both adefovir and lamivudine treatments improved liver health in chronic hepatitis B patients, but neither completely cleared the virus.
Supporting Evidence
- Adefovir led to HBV DNA negativity in 26.7% of patients, while lamivudine led to 13.3%.
- Both treatments resulted in significant reductions in serum ALT levels.
- There was a strong correlation between serum and hepatic HBV DNA levels before and after therapy.
Takeaway
Doctors tested two medicines to help people with a liver sickness called hepatitis B, and both helped, but neither got rid of the virus completely.
Methodology
This was a prospective randomized pilot study involving 30 patients who received either adefovir or lamivudine for 6 months, with assessments of HBV DNA levels and liver biopsies.
Limitations
The study had a small sample size and a short treatment duration of only 6 months.
Participant Demographics
21 males and 9 females, mean age 27.53 years.
Statistical Information
P-Value
P<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website